Self-Directed Mindfulness Meditation for the Reduction of Anxiety and Distress in Patients with Progressive or Recurrent Stage III or IV Gynecologic Cancers
- Have a diagnosis of stage III or IV, progressive or recurrent gynecologic cancer (GC) (endometrial, ovarian, fallopian tube, primary peritoneal, cervical, vulvar, vaginal, or other)
- Be native English speakers
- Report >= 4 on the National Cancer Care Network (NCCN) Distress Thermometer at the time of recruitment
- Not currently be practicing weekly meditation
- Be willing to create (or already have) an email address
- Have access to internet via a personal electronic device (or be willing to borrow an internet-enabled tablet from the study team)
- Distress Thermometer ratings =< 3
- Non-native English speakers
- Individuals with severe depression
- Individuals who are having suicidal thoughts
- Individuals who are also not willing to create an email address for the purpose of the study (or individuals who do not have an email address already) will not be eligible
- Individuals who are not currently practicing weekly meditation will also not be eligible
- Due to overlap in surveys for other ongoing trials in the Division of Gynecologic Oncology, patients may not be currently enrolled on protocol Institutional Review Board (IRB)#: 201511102 (chemoresistance) or IRB# 201804169 (cytokine-induced depression)
I. To investigate effects of the mindfulness meditation intervention compared to usual care on anxiety and other psychological outcomes.
II. To investigate effects of the mindfulness meditation intervention compared to usual care on physical distress outcomes.
III. To assess patient acceptability of the mindfulness meditation intervention.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients listen to a mindfulness meditation recording over 20-25 minutes daily for 3 weeks.
ARM II: Patients receive usual care.
After completion of study, patients are followed up at 1 month.
Trial Phase Phase NA
Trial Type Supportive care
Siteman Cancer Center at Washington University
- Primary ID 201905188
- Secondary IDs NCI-2019-05876
- Clinicaltrials.gov ID NCT04072406